Protocol

The Japanese Early-Stage Trial of High-Dose Methylcobalamin for Amyotrophic Lateral Sclerosis (JETALS): Protocol for a Randomized Controlled Trial

Ryosuke Oki, MD; Yuishin Izumi, MD, PhD; Hiroyuki Nodera, MD, PhD; Yasutaka Sato, MBBS; Hiroshi Nokihara, MD, PhD; Kazuaki Kanai, MD, PhD; Masahiro Sonoo, MD, PhD; Makoto Urushitani, MD, PhD; Kazuto Nishinaka, MD; Naoki Atsuta, MD, PhD; Nobuo Kohara, MD, PhD; Toshio Shimizu, MD, PhD; Hitoshi Kikuchi, MD, PhD; Masaya Oda, MD, PhD; Ken Ikeda, MD, PhD; Makiko Nagai, MD, PhD; Kiyonobu Komai, MD, PhD; Yusuhito Kojima, MD; Daisuke Kuzume, MD; Sagiri Isose, MD, PhD; Shun Shimohama, MD, PhD; Koji Abe, MD, PhD; Hidefumi Ito, MD, PhD; Kazuyuki Noda, MD, PhD; Tatsuo Kagimura, PhD; Kensuke Noma, MD, PhD; Hiroaki Yanagawa, MD, PhD; Satoshi Kuwabara, MD, PhD; Ryuji Kaji, MD, PhD; JETALS

1Department of Clinical Neuroscience, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan
2Clinical Trial Center for Developmental Therapeutics, Tokushima University Hospital, Tokushima, Japan
3Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan
4Department of Neurology, Teikyo University School of Medicine, Tokyo, Japan
5Department of Neurology, Shiga University of Medical Science, Otsu, Japan
6Department of Neurology, Sumitomo Hospital, Osaka, Japan
7Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan
8Department of Neurology, Kobe City Medical Centre General Hospital, Kobe, Japan
9Department of Neurology, Tokyo Metropolitan Neurological Hospital, Tokyo, Japan
10Department of Neurology, Murakami Karindo Hospital, Fukuoka, Japan
11Department of Neurology, Vihara Hananosato Hospital, Miyoshi, Japan
12Department of Neurology, Toho University Omori Medical Center, Tokyo, Japan
13Department of Neurology, Kitasato University East Hospital, Sagamihara, Japan
14Department of Neurology, National Hospital Organization Iou Hospital, Kanazawa, Japan
15Department of Neurology, Takeda General Hospital, Kyoto, Japan
16Department of Neurology, Chikamori Hospital, Kochi, Japan
17Department of Neurology, National Hospital Organization Chiba-East Hospital, Chiba, Japan
18Department of Neurology, Sapporo Medical University, Sapporo, Japan
19Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan
20Department of Neurology, Wakayama Medical University, Wakayama, Japan
21Department of Neurology, Juntendo University Shizuoka Hospital, Izunokuni, Japan
22Department of Neurology, Brain Research Institute, Niigata University, Niigata, Japan
23Division of Neurology, Department of Internal Medicine, Jichi Medical University, Tochigi, Japan
24Department of Neurology and Geriatrics, Gifu University Graduate School of Medicine, Gifu, Japan
25Department of Biostatistics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
26Translational Research Center for Medical Innovation, Foundation for Biomedical Research and Innovation, Kobe, Japan
27Division of Regeneration and Medicine, Medical Center for Translational and Clinical Research, Hiroshima University Hospital, Hiroshima, Japan
28Department of Cardiovascular Regeneration and Medicine, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
29Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan

Corresponding Author:
Yuishin Izumi, MD, PhD
Department of Clinical Neuroscience
Institute of Biomedical Sciences
Abstract

**Background:** Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that affects the upper and lower motor neurons. Currently, only riluzole and edaravone are approved as drugs to treat ALS and new agents with larger effect sizes are warranted. Exploratory analyses in our previous study (study ID #E0302-J081-761) have suggested that high-dose methylcobalamin (E0302) prolonged the overall survival of ALS patients and suppressed ALS progression in patients with a disease duration of less than 12 months.

**Objective:** This clinical trial aims to evaluate the efficacy and safety of E0302 for treatment of ALS patients within one year of onset.

**Methods:** The Japanese early-stage trial of high-dose methylcobalamin for ALS (JETALS) is a prospective, multicenter, placebo-controlled, double-blind, randomized phase III study conducted at 24 tertiary neurology centers and is funded by the Japan Agency for Medical Research and Development. A total of 128 ALS patients within one year of onset were randomized at a 1:1 ratio to receive intramuscular injection with E0302 50 mg or placebo twice a week for 16 weeks. The primary endpoint is changes in the ALS Functional Rating Scale-Revised (ALSFRS-R) total score at 16 weeks. If patients wish to receive E0302 50 mg after the double-blind administration period, E0302 will be provided to them until March 2020 during the continuous administration period.

**Results:** This study began in October 2017 and is being conducted at 24 participating institutions in Japan. The study is in progress and the patient enrollment period is scheduled to end in August 2019, with follow-up scheduled to end in March 2020.

**Conclusions:** This study is being performed to revalidate the efficacy and safety of E0302 in patients with early-stage ALS in the first year of symptom onset. If positive results are obtained, the aim is to apply for E0302 approval as a new drug for the treatment of ALS.

**Trial Registration:** ClinicalTrials.gov NCT03548311; https://clinicaltrials.gov/ct2/show/NCT03548311 (Archived by WebCite at http://www.webcitation.org/74Fw3rDzb)

**International Registered Report Identifier (IRRID):** PRR1-10.2196/12046

**KEYWORDS**

amyotrophic lateral sclerosis; methylcobalamin; vitamin B12; JETALS; clinical trial

Introduction

Amyotrophic lateral sclerosis (ALS) is a disease of unknown etiology that affects upper and lower motor neurons and results in progressive systemic muscle weakness and atrophy. The median survival time—period from onset until the use of an invasive respiratory support device or death—is 20-48 months [1].

Many drugs have been evaluated in clinical trials for treating patients with ALS; however, apart from riluzole and edaravone, none have been approved by the US Food and Drug Administration. Riluzole has been shown to prolong survival by 2-3 months [2]. Edaravone has been shown to slow the advance of the ALS Functional Rating Scale-Revised (ALSFRS-R) score: the least-squares mean difference during 24 weeks between the edaravone group and the placebo group was 2.49 (SE 0.76, 95% CI 0.99-3.98; \textit{P}=0.001) in favor of edaravone [3].

Hence, the development of a drug that extends the survival time or ameliorates clinical symptoms of ALS is widely anticipated. High-dose methylcobalamin—an active form of vitamin B12—has been suggested to have a protective effect against neurodegeneration in vitro and in vivo [4-7]. Clinical research reports have suggested that administration of high-dose methylcobalamin to patients with ALS has yielded clinically beneficial results [8,9].

In one study, methylcobalamin (0.5 or 25 mg/day) was intramuscularly administered for 14 days to 24 patients with ALS [8]. As a result, the compound muscle action potential amplitude in the 25 mg methylcobalamin group was significantly increased after 4 weeks—2 weeks after administration was completed—compared with that before administration of methylcobalamin.

The aforementioned nonclinical and clinical research results showed that high-dose methylcobalamin may be an effective treatment option for ALS. Owing to the favorable safety and pharmacokinetic results in the phase I clinical study, the
subsequent phase II and III clinical studies targeting Japanese
patients with ALS (study ID #E0302-J081-761) were conducted
by Eisai Co, Ltd, hereinafter referred to as Eisai [9]. In that
study, patients who were diagnosed with definite, probable, or
probable-laboratory-supported ALS using revised El Escorial
criteria within three years after symptom onset were enrolled
and randomly assigned to receive placebo, E0302 (methylcobalamin) 25 mg, or E0302 50 mg intramuscularly
twice weekly for 182 weeks. Primary endpoints were event-free
survival (ie, time until death, invasive respiratory support device,
or all-day noninvasive respiratory support device) and
ALSFRS-R changes. In their study, 370 patients were
analyzed—placebo (n=123), E0302 25 mg (n=124), and E0302
50 mg (n=123). Results showed that the E0302 25 mg and 50
mg groups had a tendency to surpass the placebo group with
respect to ALSFRS-R total score as one of the primary
endpoints, but did not go as far as indicating statistical
significance.

In another study, 144 patients who were given a diagnosis of
ALS within 12 months after symptom onset were analyzed—placebo (n=48), E0302 25 mg (n=54), and E0302
50 mg (n=42) [10]. The median event-free survival was 570
days, 1087 days, and 1197 days, respectively, which was
prolonged in a dose-dependent manner (E0302 25 mg hazard
eratio 0.64, 95% CI 0.38-1.09; E0302 50 mg hazard ratio 0.50,
95% CI 0.27-0.93; P=.01). In addition, ALSFRS-R changes
were smaller in both E0302 groups (E0302 25 mg plus E0302
50 mg, P=.003; E0302 50 mg, P=.01) [10]. Although this
observation was noted only in the results of the subpopulation
analysis, the fact that high-dose methylcobalamin showed high
efficacy in patients with ALS who were diagnosed early and
registered in the study is considered clinically significant.

In this study, the incidence of adverse events was high, but the
incidence of adverse reactions was limited. No obvious
difference was observed between the placebo, the E0302 25
mg, and the E0302 50 mg groups in the occurrence of adverse
events or reactions and there was no issue with the safety of
intramuscular administration of E0302 25 mg or E0302 50 mg.
One case of death by cardiac arrest was observed as a serious
adverse reaction in the E0302 50 mg group, which was
determined to be “possibly related” to the investigational
product, since this association cannot be completely ruled out.

Based on the results of the phase II and III clinical studies
conducted by Eisai, we planned to conduct an investigator-initiated trial to confirm the efficacy and safety of
E0302 50 mg for treatment of ALS patients within one year
after onset. In this trial, we adopted the updated Awaji criteria
for the first time in the world, to our knowledge, which has
displayed higher sensitivity compared to the El Escorial/revised
Airlie House diagnostic criteria [11]. We adopted the updated
Awaji criteria because we needed to increase the registration
rate as much as possible, due to the enrollment of the early-stage
patients. Our primary endpoint was the variation in the
ALSFRS-R total score from allocation day to 16 weeks of

Methods

Trial Design Overview

This Japanese early-stage trial of high-dose methylcobalamin
for ALS (JETALS) is a multicenter, randomized, placebo-controlled, double-blind, parallel-group comparative
study. It comprises three study periods: observation, treatment,
and continuing administration (see Figure 1). The eligibility of
participants who registered for the observation period will be
determined at the end of the 12-week observation period. Those
confirmed as eligible will be registered in the treatment period
and allocated to the placebo group or the E0302 50 mg group
through dynamic allocation.

Randomization will be performed using a central registration
system. Allocation will be done using a modification of the
minimization method, which is a dynamic allocation method
used to avoid selection bias in medical institutions. The
investigational product will be allocated according to the patient
registration sequence, taking into consideration the following
criteria: disease type (ie, bulbar onset, upper-limb onset,
and lower-limb onset); ALS severity at the end of the
observation period (ie, grade 1 or 2 according to Japan ALS
severity classification, which ranges from grade 1 to 5, with
grade 5 being the most severe); time from symptom onset to
the start of the observation period (ie, ≤9 months or >9 months
and ≤12 months); forced vital capacity (FVC) at the end of the
observation period (ie, <90% or ≥90%), and edaravone
administration history (ie, no or yes). These patient
characteristics will be used as the allocation adjustment factors
(ie, minimization factors) in consideration of the balance of
groups within each facility and the overall balance.

E0302 50 mg or placebo will be intramuscularly administered
twice weekly from the administration start date until the end of
the 16-week treatment period. Investigational product
administration and its efficacy, safety, and ALSFRS-R
assessment will be conducted by various independent personnel
to ensure as much blinding as possible during the treatment
period. The efficacy, ALSFRS-R, and safety assessors will
conduct necessary assessments at 4, 8, and 16 weeks after the
start of investigational product administration, as well as at the
time of event onset and at the time of discontinuation. All
ALSFRS-R assessors underwent an ALSFRS-R training
program, following the procedure manual made for this study.

The primary endpoint is a variation in the ALSFRS-R total score
from allocation day until week 16 of treatment. Safety endpoints
are adverse events, laboratory test results, electrocardiogram
measurements, and vital sign measurements.

Subjects who wish to continue administration after week 16 of
treatment will be transferred to the continuing administration
period and they may continue treatment with E0302 50 mg until
March 2020 at the latest. Independent assessment will not be
necessary during the continuing administration period as
investigators will conduct safety and efficacy assessments. The
patients’ self-administration and the administration by their
families and home-visit nurses at their homes will also be
allowed in the continuing administration period.
Eligibility Criteria
Target patients are those who were diagnosed with sporadic or familial ALS corresponding to the categories of definite, probable, or probable-laboratory-supported in the updated Awaji criteria (see Table 1) [11]. Inclusion and exclusion criteria are listed in Textbox 1; patients who satisfy all of the criteria will be included.

Patients will be considered as eligible participants according to the following: those who satisfied inclusion criteria 1-4, 6, and 7 when the observation period started; those who satisfied inclusion criteria 3 and 5-7 when the observation period was completed; those who did not meet any of the exclusion criteria when the observation period started; and those who did not meet exclusion criteria 1-4, 7-11, 13, and 14 when the observation period was completed.

Interventions
During the treatment period, the patients will be administered with E0302 50 mg/day, or a placebo intramuscularly twice weekly. During the continuous administration period, patients will be administered with E0302 50 mg/day, depending on each patient’s request.

Outcomes
The primary endpoint is a variation in the ALSFRS-R total score from allocation day until week 16 of the treatment period. The secondary endpoints are the time from allocation day until the onset of an event (ie, 24-hour use of noninvasive respiratory support equipment, use of invasive respiratory support, or death) as well as variation in FVC, blood homocysteine concentration, the manual muscle test total score, grip strength (both left and right), the Norris scale total score, and the Amyotrophic Lateral Sclerosis Assessment Questionnaire-40 (ALSAQ-40) total score. The safety endpoints are adverse events, laboratory test results, electrocardiogram measurements, and vital sign measurements. The endpoints during the continuing administration period are the time from allocation day until the onset of an adverse event (ie, 24-hour use of noninvasive respiratory support equipment, use of invasive respiratory support, or death) as well as variation in the ALSFRS-R total score, laboratory test results, electrocardiogram measurements, vital sign measurements, and adverse events.

Sample Size and Trial Duration
The target number of subjects is 128—placebo group (n=64) and E0302 50 mg group (n=64). In the previous study (ie, study ID #E0302-J081-761), the difference in the ALSFRS-R total score was estimated using data from a subpopulation of patients who were within one year of symptom onset when the observation period started and whose ALSFRS-R total score decreased by 1-2 points during the observation period (ie, 12 weeks) [10]. Based on the results of this subgroup analysis, we hypothesized that the E0302 50 mg group’s score would exceed that of the placebo group by the difference in the ALSFRS-R total scores. The required number of subjects to set the type I error probability to ≤2.5% in the one-sided tests and to set the statistical power to ≥80% was a minimum of 60 patients per group, based on the subgroup population result. Considering that there will be discontinuations during the study, the target number of patients for this study was determined to be 64 patients per group.

The planned patient registration period is from October 2017 to September 2019; the planned study implementation period is from October 2017 to March 2020.
Table 1. Updated Awaji criteria.

<table>
<thead>
<tr>
<th>Diagnosis grade</th>
<th>Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Definite</td>
<td>Clinical or neurophysiological evidence of upper and lower motor neuron dysfunction in the bulbar region and in at least two spinal regions or three spinal regions</td>
</tr>
<tr>
<td>Probable</td>
<td>Clinical or neurophysiological evidence of upper and lower motor neuron dysfunction in at least two regions, with some upper motor neuron signs necessarily rostral (above) to lower motor neuron dysfunction</td>
</tr>
<tr>
<td>Probable-laboratory-supported</td>
<td>Clinical signs of upper and lower motor neuron dysfunction in one region together with neurophysiological evidence of lower motor neuron dysfunction in two regions</td>
</tr>
<tr>
<td>Possible</td>
<td>Clinical or neurophysiological evidence of upper and lower motor neuron dysfunction in one region or upper motor neuron signs evident in two regions or lower motor neuron dysfunction evident rostral (above) to upper motor neuron signs</td>
</tr>
</tbody>
</table>

Textbox 1. Inclusion and exclusion criteria for the study.

**Inclusion criteria:**
1. Patients from whom written consent to participate in this study was received
2. Patients who are ≥20 years of age at the time of providing informed consent
3. Patients diagnosed with sporadic or familial amyotrophic lateral sclerosis (ALS) corresponding to the categories of definite, probable, or probable-supported in the updated Awaji criteria
4. Patients who are within one year of symptom onset when the observation period started
5. Patients whose ALSFRS-R (Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised) total score has decreased by 12 points during the observation period (12 weeks)
6. Patients who are rated as 1 or 2 according to Japan ALS severity classification (grade 1-5, grade 5 most severe)
7. Patients seen on an outpatient basis

**Exclusion criteria:**
1. Patients who have undergone a tracheostomy
2. Patients who are using a noninvasive respiratory support device
3. Patients with ≤60% forced vital capacity
4. Patients with chronic obstructive pulmonary disorder
5. Patients with vitamin B12 deficiency-based neurological symptoms
6. Patients who have received edaravone within four weeks prior to observation period registration
7. Patients who have started riluzole, changed the dosage, or discontinued the medication after giving informed consent
8. Patients with cognitive impairment
9. Patients who are or may be pregnant
10. Patients with a serious respiratory disorder, cardiovascular disease, or liver or kidney disease
11. Patients with a malignant tumor
12. Patients who have participated in another trial within the 12 weeks prior to giving informed consent
13. Patients with current illness or those with a history of drug allergy or severe allergic disease (anaphylactic shock)
14. Patients who are determined to be unsuitable for this study by the investigator or subinvestigator

Statistical Considerations

The analysis sets for efficacy analysis are full analysis set and per protocol set. Full analysis set includes subjects who received the investigational product at least one time; this is the primary analysis set. Per protocol set is the secondary analysis set for confirming consistency of the results obtained from full analysis set from a sensitivity analysis standpoint. The safety analysis set refers to the set of subjects registered for the treatment period, excluding those who have no assessable safety data.

For the analysis of the primary endpoint, the difference in the ALSFRS-R scores from allocation day to each time point is the response variable; the administration groups, time points, minimization factors, and interaction between the administration groups and time points are the fixed effects. The ALSFRS-R total score on allocation day is the covariate and fits the linear model—Mixed-Model Repeated Measure analysis—with an unstructured covariance structure of the error variance. If the lower limit of the 95% confidence interval of the least mean square is over zero for the difference in the variation in the
ALSFRS-R total scores at week 16 when comparing the placebo and E0302 50 mg groups, then it will be determined to be statistically significant. The significance level of the efficacy endpoints is set at one-tailed 2.5%.

Ethics and Dissemination

The study protocol was approved by the Institutional Review Board at each site before the start of the trial. Substantial amendments of the study protocol must be approved by each Institutional Review Board. The trial was registered at ClinicalTrials.gov (NCT03548311) and the University Hospital Medical Information Network clinical trials registry (UMIN000029588). Written informed consent will be obtained directly from each patient.

Results

This study began in October 2017 and is being conducted at 24 participating institutions in Japan. The study is in progress and the patient enrollment period is scheduled to end in August 2019, with follow-up scheduled to end in March 2020.

Discussion

JETALS is a study that aims to verify the superiority of high-dose E0302 (methylcobalamin, 50 mg) intramuscular administration over placebo and to examine its safety in patients with ALS using the Japanese version of the ALSFRS-R as an indicator. Two revisions were made to the protocol of a previous study (study ID #E0302-J081-761), which was conducted as a preliminary study, targeting patients with ALS who were within one year of symptom onset.

The first revision changed the primary endpoint to a variation in the ALSFRS-R total score from allocation day to week 16 of treatment. The ALSFRS-R is a clinical assessment scale created to objectively and quantitatively assess the progress of patients with ALS. This scale can be used to clinically assess the motor function of the extremities, bulbar function, and respiratory function disorders. The ALSFRS-R score is frequently used as the primary endpoint in recent clinical studies targeting ALS. Because the ALSFRS-R is highly reliable for assessing ALS clinical symptoms using both the total score and item scores, and it can be used in clinical assessments, a variation in the ALSFRS-R total score was selected as the primary endpoint of this study [12]. Variations between different assessors may be minimized by having each assessor master the scale in advance through a training program. In our previous study (study ID #E0302-J081-761), the ALSFRS-R scores were evaluated at 4 and 16 weeks. For the patients who were given a diagnosis of ALS within 12 months after symptom onset, we predicted that after 16 weeks of treatment, it would be possible to detect a significant difference (data not shown). In addition, the ratio of ALSFRS-R scores between first symptom and first examination, during whole disease or within 100 days, correlates with survival time [13], hence the ALSFRS-R score at 16 weeks is thought to be a clinically important predictive factor of survival time. That is why we set the period of primary outcome evaluation at 16 weeks, from the points of view of effectiveness and ethics.

The second modification was changing the diagnostic criteria from the El Escorial/revised Airlie House diagnostic criteria to the updated Awaji criteria. The El Escorial/revised Airlie House diagnostic criteria are widely accepted, but their low diagnostic sensitivity has been considered an issue [14]. The reason for this low sensitivity can be attributed to the few cases in which widespread denervation is triggered in the early phase. In addition, another disadvantage of the El Escorial/revised Airlie House diagnostic criteria is that fasciculation potential, which is observed in the early phase of ALS, is not included in the electrodiagnostic criteria. The updated Awaji diagnostic criteria are advocated as an algorithm for combining the Awaji electrodiagnostic criteria and the El Escorial/revised Airlie House diagnostic criteria without variance [11]. In other words, the same framework as the El Escorial/revised Airlie House diagnostic criteria is maintained (ie, definite, probable, probable-laboratory-supported, and possible) and fasciculation potential is included as evidence of active denervation.

Geevasinga et al examined the testing sensitivity of each set of diagnostic criteria for 881 patients with ALS from 8 articles reported previously [11]. Data from 7 out of these 8 (88%) articles indicated that applying the updated Awaji diagnostic criteria over the El Escorial/revised Airlie House diagnostic criteria increased sensitivity, implying that the updated Awaji diagnostic criteria are definitely more advantageous.

This study targeted patients with ALS who were within one year of onset. Therefore, we used the updated Awaji diagnostic criteria, with its increased diagnostic sensitivity. Effects on efficacy assessment when using diagnostic criteria that differs from that used in the previous study needed to be confirmed. To this end, an analysis was conducted that narrowed down subpopulations corresponding to clinically definite, probable, and probable-laboratory-supported ALS based on the El Escorial/revised Airlie House diagnostic criteria. This was done when the observation period was completed and the effect of the criteria on the primary endpoint was examined.

Currently, only riluzole and edaravone have been approved as treatment drugs for ALS worldwide, but their effects are limited. As with the results of the subpopulation analysis, E0302 prolonged event-free survival more than 600 days and slowed the advance of the ALSFRS-R total score by 3.3 during 16 weeks; its safety and tolerability was well-established in the previous study [10]. Therefore, E0302 is highly anticipated as a new drug for treating ALS. E0302 can be used not only for monotherapy, but for multitherapy with riluzole and edaravone, which could change the strategy of ALS treatment.
Acknowledgments

This work is funded and supported by the Japan Agency for Medical Research and Development under the agency’s Practical Research Project for Rare Intractable Diseases program (project #17ek0109252h0001). This work is also supported by Grants-in-Aid from the Research Committee of CNS Degenerative Diseases, the Ministry of Health, Labour and Welfare of Japan. We would like to thank all the investigators and study coordinators involved in the trial.

The following individuals and institutions participated in the JETALS study (JETALS collaborators): Kenshi Takechi, Kazuki Maeda, Akari Futami, and Yumi Ishida, Clinical Trial Center for Developmental Therapeutics, Tokushima University Hospital, Tokushima, Japan; Kazumoto Shibuya, Department of Neurology, Chiba University Graduate School of Medicine, Chiba, Japan; Taiji Tsunemi, Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan; Yuki Hatanaka, Department of Neurology, Teikyo University School of Medicine, Tokyo, Japan; Hyo Kim, Department of Neurology, Shiga University of Medical Science, Otsu, Japan; Ryoichi Nakamura and Naoki Hayashi, Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan; Akihiro Kawata, Department of Neurology, Tokyo Metropolitan Neurological Hospital, Tokyo, Japan; Chiho Ishida, Department of Neurology, National Hospital Organization Iou Hospital, Kanazawa, Japan; Jun Kawamata, Department of Neurology, Sapporo Medical University, Sapporo, Japan; Yasuyuki Ohta, Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan; Yoshiaki Nakayama, Department of Neurology, Wakayama Medical University, Wakayama, Japan; Susumu Onodera, Department of Neurology, Brain Research Institute, Niigata University, Niigata, Japan; Yuichiro Hayashi, Department of Neurology and Geriatrics, Gifu University Graduate School of Medicine, Gifu, Japan; Tatsushi Toda, Department of Neurology, The University of Tokyo, Tokyo, Japan; Hirofumi Maruyama, Department of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan; Hirokazu Furuya, Department of Neurology, Kochi Medical School, Kochi University, Kochi, Japan.

Conflicts of Interest

The investigational product is provided by Eisai Co, Ltd.

References


Abbreviations

ALS: amyotrophic lateral sclerosis
ALSASSQ-40: Amyotrophic Lateral Sclerosis Assessment Questionnaire-40
ALSFRS-R: Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised
E0302: methylcobalamin
FVC: forced vital capacity
JETALS: Japanese early-stage trial of high-dose methylcobalamin for ALS